Investigation of the Disease Process and Some Blood Parameters of Patients with COVID-19 Positive Diagnosis Registered at The Family Health Center

Yıl 2022, Cilt: 15 Sayı: 3, 233 - 243, 30.12.2022

Mehmet Anasız Dilek Kuzay

https://doi.org/10.52976/vansaglik.1022178

Öz

Aim: The aim of this study is to investigate the course of the disease and the variables of blood parameters in the light of the information obtained from patients with a positive diagnosis of Covid-19. In this way, it is thought that Covid-19 disease can be diagnosed and its prognosis can be determined as soon as possible.
Method: File records of 113 patients enrolled in a family health center between April 2020 and December 2020 were retrospectively reviewed. From biochemical blood tests, platelet (PLT), lymphocyte (LYM), lymphocyte % (LYM ½), monocytes (MONO), % monocytes (MONO ½) and neutrophil counts, neutrophil/lymphocyte ratio (NLR), C- Reactive Protein (CRP), Ferritin, Lactate Dehydrogenase (LDH), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Creatine kinase (CK), Troponin, Hematocrit (HTC), and Hemoglobin (HGB) results were examined.
Findings: When compared according to gender, AST, ALT, CK, LDH, HGB, HCT, Ferritin, Monocyte and Troponin levels were found to be higher in males and lower platelet levels than females (p<0.05). In the presence of lung involvement, CRP, LDH, AST, neutrophil, ferritin, troponin, LYM ½ and NLR levels were higher than in the absence of lung involvement, and MONO½ levels were lower in the presence of lung involvement (p<0.05). In the presence of chronic disease, CRP, AST, ALT, LDH, and Troponin levels were higher than in the absence of chronic disease, while MONO½ and MONO levels were lower (p<0.05).
Conclusion: According to the results of our study, male gender, high AST, ALT, Ferritin, Troponin, CRP and LDH levels, and low Monocyte levels may be poor prognostic criteria for COVID-19. Hematological and biochemical parameters can be used as predictive markers during the treatment process, both at the time of admission for diagnostic purposes and in determining the severity and prognosis of the disease, as well as the follow-up of the treatment.

Anahtar Kelimeler

COVID-19, SARS-CoV-2, Biomarkers, Hematologic Tests, Prognosis, Gender Identity

Aile Sağlığı Merkezinde Kayıtlı Olan COVID-19 Pozitif Hastaların Hastalık Süreci ve Bazı Kan Parametrelerinin İncelenmesi

Öz

Amaç: Bu çalışmanın amacı Covid-19 pozitif tanılı hastalardan alınan bilgiler ışığında hastalığın seyri ve kan parametreleri değişkenlerini araştırmaktır. Bu sayede mümkün olan en kısa sürede Covid-19 hastalığının teşhis edilebilir ve prognozu belirlenebilir.
Yöntem: Nisan 2020 ile Aralık 2020 tarihleri arasında bir aile sağlığı merkezinde kayıtlı olan 113 hastanın retrospektif olarak dosya kayıtları incelenerek yapılmıştır. Biyokimyasal kan testlerinden trombosit (PLT), lenfosit (LYM), % lenfosit (LYM ½), monosit (MONO), % monosit (MONO ½) ve nötrofil sayıları, nötrofil/lenfosit oranı (NLR), C- Reaktif Protein (CRP), Ferritin, Laktat Dehidrojenaz (LDH), Aspartat aminotransferaz (AST), Alanin aminotransferaz (ALT), Kreatin kinaz (CK), Troponin, Hematokrit (HTC), ve Hemoglobin (HGB) sonuçları incelenmiştir.
Bulgular: Cinsiyete göre karşılaştırma yaptığımızda erkeklerde AST, ALT, CK, LDH, HGB, HCT, Ferritin, Monosit ve Troponin düzeyleri kadınlara göre yüksek, trombosit düzeylerinin ise düşük olduğu tespit edilmiştir (p<0.05). Akciğer tutulumu varlığında CRP, LDH, AST, nötrofil, ferritin, troponin, LYM ½ ve NLR düzeylerinin akciğer tutulumu yokluğuna göre daha yüksek, MONO½ düzeylerinin ise akciğer tutulumu varlığında düşük olduğu belirlenmiştir (p<0.05). Kronik hastalık varlığında CRP, AST, ALT, LDH ve Troponin düzeyleri kronik hastalık yokluğuna göre yüksek, MONO½ ve MONO düzeylerinin ise düşük olduğu belirlenmiştir (p<0.05).
Sonuç: Çalışmamız sonuçlarına göre erkek cinsiyet, yüksek AST, ALT, Ferritin, Troponin, CRP ve LDH düzeyleri ve düşük Monosit düzeyleri COVİD-19 için kötü prognoz kriteri olabilir. Hematolojik ve biyokimyasal parametreler tedavinin takibi yanı sıra gerek tanısal amaçla başvuru sırasında, gerekse de hastalığın şiddetinin, prognozunun belirlenmesinde tedavi sürecinde prediktif belirteçler olarak kullanılabilirler.

Anahtar Kelimeler

COVİD-19, SARS-CoV-2, Hematolojik parametreler, Biyokimyasal parametreler, Prognoz, Cinsiyet

Kaynakça

• Beniac DR, Andonov A, Grudeski E, Booth TF. (2006). Architecture of the SARS coronavirus prefusion spike. Nature Structural & Molecular Biology, 13(8):751-2.
• Cheng L, Li H, Li L, Liu C, Yan S, et al. Ferritin in the coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis. (2020). Journal of Clinical Laboratory Analysis, 34(10):1–18.
• Ceccarelli M, Berretta M, Venanzi Rullo E, Nunnari G, Cacopardo B. (2020). Differences and similarities between severe acute respiratory syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet? European Review for Medical and Pharmacological Sciences, 24(5):2781-2783.
• Chan JF, Kok KH, Zhu Z, Chu H, To KK, et al. (2020). Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes & Infections, 28;9(1): 221-236.
• Chen T, Wu D, Chen H, Yan W, Yang D, et al. (2020). Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. British Medical Journal, 368:m1091.
• Doğan Ö, Devrim E. (2020). Tanı ve İzlemde Laboratuvar Testleri. COVID‐19 içinde Ed: Memikoğlu O, Genç V. E‐Kitap Ankara Üniversitesi Basımevi, 35‐40.
• Elshazli RM, Toraih EA, Elgaml A, El‐Mowafy M, El‐Mesery M, et al. (2020). Diagnostic and prognostic value of hematological and immunological markers in COVID‐19 infection: A meta‐analysis of 6320 patients. PLoS One, 15(8): e0238160.
• García de Guadiana‐Romualdo L, Morell‐García D, Morales‐Indiano C, Bauça JM, Alcaide Martín MJ, et al. (2021). Characteristics and laboratory findings on admission to the emergency department among 2873 hospitalized patients with COVID‐19: the impact of adjusted laboratory tests in multicenter studies. A multicenter study in Spain (BIOCOVID‐Spain study). Scandinavian Journal of Clinical and Laboratory Investigation, 1–7.
• Guo T, Fan Y, Chen M, Wu X, Zhang L, et al. (2020). Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID‐19). JAMA Cardiology, 5(7):811.
• Gürsoy Doruk Ö, Örmen M, Tuncel P. (2021). Bıochemıcal And Hematologıcal Parameters In Covıd-19. Journal of Dokuz Eylul University Medical Faculty, 35:71-80.
• Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. (2020). Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID‐19): a meta‐analysis. Clinical Chemistry and Laboratory Medicine, 58(7):1021–8.
• Kavsak PA, de Wit K, Worster A. (2020). Emerging key laboratory tests for patients with COVID-19. Clinical Biochemistry, 81:13–4.
• Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. (2020). The role of biomarkers in diagnosis of COVID‐19 – A systematic review. Life Sciences, 254:117788.
• Kurstjens S, van der Horst A, Herpers R, Geerits MWL, Kluiters‐de Hingh YCM, et al. (2020). Rapid identification of SARS‐CoV‐2‐infected patients at the emergency department using routine testing. Clinical Chemistry and Laboratory Medicine, 58(9):1587–93.
• Lang JP, Wang X, Moura FA, Siddiqi HK, Morrow DA, et al. (2020). A current review of COVID‐19 for the cardiovascular specialist. American Heart Journal, 226: 29–44.
• Lippi G, Horvath AR, Adeli K. (2020). Editorial and Executive Summary: IFCC Interim Guidelines on Clinical Laboratory testing during the COVID‐19 Pandemic. Clinical Chemistry and Laboratory Medicine, 58(12): 1965–9.
• Muniyappa R, Gubbi S. (2020). COVID-19 pandemic, coronaviruses, and diabetes mellitus. American Journal of Physiology-Endocrinology and Metabolism, 318: E736-E41.
• O’Shea PM, Lee GR, Griffin TP, Tormey V, Hayat A, et al. (2020). COVID‐19 in adults: test menu for hospital blood science laboratories. Irish Journal of Medical Science, 189(4):1147–52.
• Pourbagheri‐Sigaroodi A, Bashash D, Fateh F, Abolghasemi H. (2020). Laboratory findings in COVID‐19 diagnosis and prognosis. Clinica Chimica Acta, 510:475–82.
• Qin C, Zhou L, Hu Z, Zhang S, Yang S, et al. (2020). Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID‐19) in Wuhan, China. Clinical Infectious Diseases, 71(15):762–8.
• Rizzo P, Vieceli Dalla Sega F, Fortini F, Marracino L, Rapezzi C, et al. (2020). COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm? Basic Research in Cardiology, 115: 31.
• Song Z, Xu Y, Bao L, Zhang L, Yu P, et al. (2019). From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses, 11: 59. Siddiqi HK, Mehra MR. (2020). COVID‐19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. The Journal of Heart and Lung Transplantation, 39(5):405–7.
• Thompson S, Bohn MK, Mancini N, Loh TP, Wang CB, et al. (2020). IFCC Interim Guidelines on Biochemical/Hematological Monitoring of COVID‐19 Patients. Clinical Chemistry and Laboratory Medicine, 58(12):2009–16.
• Yazar H, Kayacan Y, Ozdin M. (2020). De Ritis ratio and biochemical parameters in COVID-19 patients. Archıves Of Physıology And Bıochemıstry, 1-5.
• Yuan J, Zou R, Zeng L, Kou S, Lan J, et al. (2020). The correlation between viral clearance and biochemical outcomes of 94 COVID‐19 infected discharged patients. Inflammation Research, 69(6):599‐606.
• Zhou Y, Yang Y, Huang J, Jiang S, Du L. (2019). Advances in MERS-CoV vaccines and Therapeutics Based on the Receptor-Binding Domain. Viruses, 11(1):60.